Accelerating drug discovery with AI: Insights from Isomorphic Labs
Gradient Dissent: Conversations on AIShow Notes
In this episode of Gradient Dissent, Isomorphic Labs Chief AI Officer Max Jaderberg, and Chief Technology Officer Sergei Yakneen join our host Lukas Biewald to discuss the advancements in biotech and drug discovery being unlocked with machine learning. With backgrounds in advanced AI research at DeepMind, Max and Sergei offer their unique insights into the challenges and successes of applying AI in a complex field like biotechnology. They share their journey at Isomorphic Labs, a company dedicated to revolutionizing drug discovery with AI. In this episode, they discuss the transformative impact of deep learning on the drug development process and Isomorphic Labs' strategy to innovate from molecular design to clinical trials. You’ll come away with valuable insights into the challenges of applying AI in biotech, the role of AI in streamlining the drug discovery pipeline, and peer into the future of AI-driven solutions in healthcare. Connect with Sergei Yakneen & Max Jaderberg: https://www.linkedin.com/in/maxjaderberg/ https://www.linkedin.com/in/yakneensergei/ https://twitter.com/SergeiIakhnin https://twitter.com/maxjaderberg Follow Weights & Biases: https://twitter.com/weights_biases https://www.linkedin.com/company/wandb
More from Gradient Dissent: Conversations on AI
Can today's power grid handle the explosive growth of AI data centers? Tesla Alum Drew Baglino, now founder & CEO of Heron Power, doesn't think so.
Should American companies be worried about Chinese open-source AI models?
"We are going to switch from the problem in AI being that nothing works to the problem being that everything works."
Samuel Rodriques left physics because there were no unsolved problems left. Instead, he built an AI scientist named Kosmos to cure every disease, solve aging, and map the human brain. In this episode: The cure his AI proposed for blindness Why he would never touch a peptide Whether we'll need human scientists in 20 years What's stopping America in drug discovery
"Every vehicle is capable of driverless operation. That's clearly the steady state of where we're going." Wayve started in a rented house in Cambridge with $1.5M, a car in the garage, and an aim to integrate end-to-end AI into driving. A decade later it's driven across 506 cities without a single HD map and is worth over $8.6 billion. In this episode, CEO Alex Kendall joins Lukas Biewald to talk about how he built the AI driver Uber, Nvidia, Mercedes, and Nissan all backed, and why putting self-driving AI into 100 million cars a year is a far bigger bet than 10,000 robotaxis. Waymo and Tesla both come up. He doesn't shy away.